The function role of miR-181a in chemosensitivity to adriamycin by targeting Bcl-2 in low-invasive breast cancer cells

Cellular Physiology and Biochemistry

Volumn 32, Issue 5, 2013, Pages 1225-1237

  Zhu, Ying ^a   Wu, Jianzhong ^a   Li, Shuchun ^b   Ma, Rong ^a   Cao, Haixia ^a   Ji, Minghua ^a   Jing, Changwen ^a   Tang, Jinhai ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b NANJING TECH UNIVERSITY   (China)

Author keywords

Adriamycin; Bcl 2; Breast cancer; Chemosensitivity; MiR 181a

Indexed keywords

DOXORUBICIN; MESSENGER RNA; MICRORNA; MICRORNA 181A; PROTEIN BCL 2; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

3' UNTRANSLATED REGIONS; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BREAST NEOPLASMS; CELL SURVIVAL; DOWN-REGULATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; MICRORNAS; MIDDLE AGED; NEOADJUVANT THERAPY; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84890668976     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000354521     Document Type: Article

References (32)

1. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ: Effect of screening and adjuvant therapy on mortality from breast cancer. New Engl J Med 2005;353:1784-1792.
2. Craft BS, Hortobagyi GN, Moulder SL: Adjuvant biologic therapy for breast cancer. Cancer J 2007;13:156-161.
3. Harvey JM, Clark GM, Osborne CK, Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-1474.
4. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM: MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65:7065-7070.
5. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99:15524-15529.
6. Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D, Wang Y: Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues. J Gastroen Hepatol 2009;24:652-657
7. Michael MZ, O' Connor SM, van Holst Pellekaan NG, Young GP, James RJ: Reduced Accumulation of Specific MicroRNAs in Colorectal Neoplasia. Mol Cancer Res 2003;1:882-891.
8. Yoon SO, Chun SM, Han EH, Choi J, Jang SJ, Koh SA, Hwang S, Yu E: Deregulated expression of microRNA-221 with the potential for prognostic biomarkers in surgically resected hepatocellular carcinoma. Hum Pathol 2011;42:1391-1400.
9. Zhou B, Li C, Qi W, Zhang Y, Zhang F, Wu JX, Hu YN, Wu DM, Liu Y, Yan TT, Jing Q, Liu MF, Zhai QW: Downregulation of miR-181a upregulates sirtuin-1 (SIRT1) and improves hepatic insulin sensitivity. Diabetologia 2012;55:2032-2043.
10. Bai H, Cao Z, Deng C, Zhou L, Wang C: miR-181a sensitizes resistant leukaemia HL-60/Ara-C cells to Ara-C by inducing apoptosis. J Cancer Res Clin 2012;138:595-602.
11. Li H, Hui L, Xu W: miR-181a sensitizes a multidrug-resistant leukemia cell line K562/A02 to daunorubicin by targeting BCL-2. Acta Bioch Bioph Sin 2012;44:269-277.
12. Zhu DX, Zhu W, Fang C, Fan L, Zou ZJ, Wang YH, Liu P, Hong M, Miao KR, Liu P, Xu W, Li JY: miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple antiapoptosis genes. Carcinogenesis 2012;33:1294-1301.
13. Zhuo L, Liu J, Wang B, Gao M, Huang A: Differential miRNA expression profiles in hepatocellular carcinoma cells and drug-resistant sublines. Oncol Rep 2013;29:555-562.
14. Lu Y, Roy S, Nuovo G, Ramaswamy B, Miller T, Shapiro C, Jacob ST, Majumder S: Anti-microRNA-222 (antimiR-222) and-181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal. J Biol Chem 2011;286:42292-42302.
15. Yu B, Sun X, Shen HY, Gao F, Fan YM, Sun ZJ: Expression of the apoptosis-related genes BCL-2 and BAD in human breast carcinoma and their associated relationship with chemosensitivity. J Exp Clin Cancer Res 2010;29:1-7.
16. Zhu W, Shan X, Wang T, Shu Y, Liu P: miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 2010;127:2520-2529.
17. Chen G, Zhu W, Shi D, Lv L, Zhang C, Liu P, Hu W: MicroRNA-181a sensitizes human malignant glioma U87MG cells to radiation by targeting Bcl-2. Oncol Rep 2010;23:997-1003.
18. Shi L, Cheng Z, Zhang J, Li R, Zhao P, Fu Z, You Y: hsa-mir-181a and hsa-mir-181b function as tumor suppressors in human glioma cells. Brain Res 2008;1236:185-193.
19. Calin G A, Croce C M. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-866.
20. Lashine YA, Seoudi AM, Salah S, Abdelaziz AI: Expression signature of microRNA-181-a reveals its crucial role in the pathogenesis of paediatric systemic lupus erythematosus. Clin Exp Rheumatol 2011;29:351-357.
21. Ryan DG, Oliveira-Fernandes M, Lavker RM: MicroRNAs of the mammalian eye display distinct and overlapping tissue specificity. Mol Vis 2006;12:1175-1184.
22. Chen CZ, Li L, Lodish HF, Bartel DP: MicroRNAs modulate hematopoietic lineage differentiation. Science 2004;303:83-86.
23. Shin KH, Bae SD, Hong HS, Kim RH, Kang MK, Park NH: miR-181a shows tumor suppressive effect against oral squamous cell carcinoma cells by downregulating K-ras. Biochem Biophys Res Commun 2011;404:896-902.
24. Gao W, Shen H, Liu L, Xu J, Xu J, Shu Y: MiR-21 overexpression in human primary squamous cell lung carcinoma is associated with poor patient prognosis. J Cancer Res Clin 2011;137:557-566.
25. Ciafrè SA, Galardi S, Mangiola A, Ferracin M, Liu CG, Sabatino G, Negrini M, Maira G, Croce CM, Farace MG: Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun 2005;334:1351-1358.
26. Gao W, Yu Y, Cao H, Shen H, Li X, Pan S, Shu Y: Deregulated expression of miR-21, miR-143 and miR-181a in non small cell lung cancer is related to clinicopathologic characteristics or patient prognosis. Biomed Pharmacother 2010;64:399-408.
27. Marton S, Garcia MR, Robello C, Persson H, Trajtenberg F, Pritsch O, Rovira C, Naya H, Dighiero G, Cayota A: Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. Leukemia 2007;22:330-338.
28. Wang Y, Yu Y, Tsuyada A, Ren X, Wu X, Stubblefield K, Rankin-Gee EK, Wang SE: Transforming growth factor-β regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM[J]. Oncogene 2010;30:1470-1480.
29. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005;433:769-773.
30. Elliott MJ, Murphy KM, Stribinskiene L, Ranganathan V, Sturges E, Farnsworth ML, Lock RB: Bcl-2 inhibits early apoptotic events and reveals post-mitotic multinucleation without affecting cell cycle arrest in human epithelial tumor cells exposed to etoposide. Cancer Chemoth Pharm 1999;44:1-11.
31. Del Bufalo D, Biroccio A, Trisciuoglio D, Bruno T, Floridi A, Aquino A, Zupi G: Bcl-2 has differing effects on the sensitivity of breast cancer cells depending on the antineoplastic drug used. Eur J Cancer 2002;38:2455-2462.
32. Yang CC, Hung PS, Wang PW, Liu CJ, Chu TH, Cheng HW, Lin SC: miR-181 as a putative biomarker for lymphnode metastasis of oral squamous cell carcinoma. J Oral Pathol Med 2011;40:397-404.